Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Treatment symbols : RETA save search
CNS Pharmaceuticals Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Published: 2024-01-17 (Crawled : 14:30) - biospace.com/
CNSP A | $0.235 -3.45% -3.57% 100K
|
Health Technology
|
| O: 5.82%
H: 7.57%
C: -7.32%
berubicin treatment pharmaceuticals glioblastoma study
CNS Pharmaceuticals' (NASDAQ:CNSP) Ongoing Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM) Continues Rapid Pace of Enrollment with 229 Patients Enrolled to Date
Published: 2023-10-11 (Crawled : 13:00) - biospace.com/
CNSP A | $0.235 -3.45% -3.57% 100K
|
Health Technology
|
| O: -2.8%
H: 18.26%
C: 13.46%
rapid berubicin treatment ongoing glioblastoma study
CNS Pharmaceuticals Provides Clinical Trial Update for Ongoing Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Published: 2023-08-03 (Crawled : 12:20) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 0.07%
H: 0.83%
C: 0.57%
CNSP A | $0.235 -3.45% -3.57% 100K
|
Health Technology
|
| O: 0.93%
H: 3.24%
C: 1.39%
berubicin update treatment ongoing pharmaceuticals trial glioblastoma study
CNS Pharmaceuticals (NASDAQ:CNSP) Achieves Over 50% Completion of Enrollment in Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Published: 2023-05-25 (Crawled : 20:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: -0.18%
H: 0.79%
C: -2.78%
CNSP A | $0.235 -3.45% -3.57% 100K
|
Health Technology
|
| O: -4.52%
H: 6.84%
C: 4.74%
berubicin treatment pharmaceuticals glioblastoma study
Over 100 Patients Now Enrolled in CNS Pharmaceuticals’ (NASDAQ: CNSP) Potentially Pivotal Study Evaluating Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Published: 2023-04-10 (Crawled : 16:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: -1.23%
H: 1.81%
C: 1.25%
CNSP A | $0.235 -3.45% -3.57% 100K
|
Health Technology
|
| O: -4.79%
H: 8.16%
C: 4.9%
berubicin treatment 100 glioblastoma study
CNS Pharmaceuticals Receives Approval from Competent Authority and Central Ethics Committee in Italy for Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM
Published: 2023-04-06 (Crawled : 14:20) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 0.79%
H: 0.86%
C: 0.6%
CNSP A | $0.235 -3.45% -3.57% 100K
|
Health Technology
|
| O: 53.58%
H: 6.02%
C: -43.6%
approval berubicin treatment pharmaceuticals global trial
CNS Pharmaceuticals Continues Momentum in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM with First Patient Enrolled in Switzerland
Published: 2023-03-09 (Crawled : 14:20) - prnewswire.com
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: -2.68%
H: 5.52%
C: 3.54%
CNSP A | $0.235 -3.45% -3.57% 100K
|
Health Technology
|
| O: -2.72%
H: 4.3%
C: -5.59%
treatment ongoing pharmaceuticals global trial berubicin momentum switzerland
CNS Pharmaceuticals Announces First Patient Enrolled in Spain in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM
Published: 2023-02-07 (Crawled : 14:00) - prnewswire.com
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 0.0%
H: 0.64%
C: -0.91%
CNSP A | $0.235 -3.45% -3.57% 100K
|
Health Technology
|
| O: -1.49%
H: 5.19%
C: -6.49%
treatment ongoing pharmaceuticals global trial berubicin
CNS Pharmaceuticals Announces Preliminary Results from Ongoing Potentially Pivotal Trial Evaluating Berubicin for the Treatment of Recurrent Glioblastoma Multiforme (GBM)
Published: 2022-12-08 (Crawled : 15:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 0.34%
H: 1.98%
C: -1.85%
CNSP A | $0.235 -3.45% -3.57% 100K
|
Health Technology
|
| O: 2.92%
H: 0.03%
C: -3.66%
treatment ongoing pharmaceuticals trial berubicin glioblastoma
Extremely Robust COVID-19 Clinical Trial Pipeline With 420+ Key Companies Expected to Change the Pace of the COVID-19 Treatment
Published: 2022-11-08 (Crawled : 16:00) - prnewswire.com
XNCR | $20.09 -1.9% -1.94% 390K
|
Health Technology
|
| O: 0.3%
H: 12.8%
C: 8.43%
VRNA | $15.82 -0.57% -0.57% 320K
|
Health Technology
|
| O: 1.35%
H: 2.31%
C: 1.09%
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 3.15%
H: 18.92%
C: 11.92%
KNSA 4 | $17.4 0.64% 0.63% 310K
|
Health Technology
|
| O: -0.13%
H: 0.26%
C: -3.81%
covid-19 treatment companies change expected trial
CNS Pharmaceuticals Announces Dosing of First Patient in Europe/France in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM
Published: 2022-11-02 (Crawled : 13:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: -0.72%
H: 4.93%
C: 0.24%
CNSP A | $0.235 -3.45% -3.57% 100K
|
Health Technology
|
| O: 5.88%
H: 15.28%
C: 11.0%
treatment ongoing pharmaceuticals global trial berubicin
CNS Pharmaceuticals Announces Activation of First Clinical Trial Sites in Europe for Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM
Published: 2022-09-28 (Crawled : 13:20) - prnewswire.com
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 2.2%
H: 9.44%
C: 6.58%
CNSP A | $0.235 -3.45% -3.57% 100K
|
Health Technology
|
| O: -4.79%
H: 9.94%
C: 7.79%
treatment europe ongoing pharmaceuticals global trial berubicin
Reata Pharmaceuticals Announces Three Month Extension of the Review Period for New Drug Application for Omaveloxolone for the Treatment of Friedreich’s Ataxia
Published: 2022-08-09 (Crawled : 11:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: -1.21%
H: 0.13%
C: -10.18%
treatment drug extension application review friedreich’s ataxia
CNS Pharmaceuticals Receives Approval from U.S. FDA for Protocol Amendment to Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM
Published: 2022-06-23 (Crawled : 13:20) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: -0.09%
H: 3.99%
C: 3.0%
CNSP A | $0.235 -3.45% -3.57% 100K
|
Health Technology
|
| O: 32.07%
H: 1.89%
C: -24.85%
treatment fda ongoing trial approval berubicin potential
Reata Pharmaceuticals Announces FDA Filing Acceptance and Priority Review Designation for the NDA for Omaveloxolone for the Treatment of Patients with Friedreich’s Ataxia
Published: 2022-05-26 (Crawled : 12:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 3.53%
H: 1.51%
C: -0.11%
treatment fda designation review friedreich’s ataxia
CNS Pharmaceuticals Receives Approval from Ethics Committee and Competent Authority in Spain for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Published: 2022-04-28 (Crawled : 19:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 2.2%
H: 0.68%
C: -0.26%
CNSP A | $0.235 -3.45% -3.57% 100K
|
Health Technology
|
| O: 8.65%
H: 0.0%
C: -6.34%
treatment approval berubicin potential glioblastoma
CNS Pharmaceuticals Receives Approval from France Ethics Committee and Competent Authority for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Published: 2022-04-06 (Crawled : 13:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: -1.09%
H: 1.8%
C: 0.45%
CNSP A | $0.235 -3.45% -3.57% 100K
|
Health Technology
|
| O: 5.16%
H: 7.69%
C: 6.16%
treatment approval berubicin potential glioblastoma
CNS Pharmaceuticals Receives Approval from Competent Authority of Switzerland for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Published: 2022-04-05 (Crawled : 14:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 0.63%
H: 1.09%
C: -2.15%
CNSP A | $0.235 -3.45% -3.57% 100K
|
Health Technology
|
| O: 0.24%
H: 29.56%
C: 14.4%
treatment approval berubicin switzerland potential glioblastoma
Reata Pharmaceuticals Completes Rolling Submission of New Drug Application for Omaveloxolone for the Treatment of Patients with Friedreich’s Ataxia
Published: 2022-03-31 (Crawled : 22:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 2.04%
H: 6.09%
C: 3.97%
treatment drug application submission friedreich’s ataxia
Reata Pharmaceuticals Initiates Rolling Submission of New Drug Application with U.S. FDA for Omaveloxolone for the Treatment of Patients with Friedreich’s Ataxia
Published: 2022-01-31 (Crawled : 15:30) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 1.0%
H: 13.68%
C: 11.81%
new drug treatment fda als application drug one submission friedreich's ataxia friedreich’s ataxia
Gainers vs Losers
| 49% | 51% |
Top 10 Gainers
KAVL | $6.275 135.02% 57.45% 44M
|
Wholesale Trade
PXMD | $0.7375 79.09% 44.16% 4.5M
|
Health Technology
DYNT | $0.371 -5.12% 43.09% 3.3M
|
Health Technology
LGVN P 3 d | $2.94 73.96% 42.52% 57M
|
HUBC | $1.94 49.23% 32.99% 73M
|
n/a
SPCB | $0.4044 46.52% 31.75% 130M
|
Electronic Technology
ONVO | $1.34 32.66% 24.62% 54M
|
Health Technology
OMQS | $0.6869 32.1% 24.3% 3.6M
|
Professional, Scientific, and T...
SNPO | $10.555 29.67% 22.88% 4M
|
AMBI | $3.72 -26.77% 21.77% 9.8K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.